The trial tested belapectin, a drug designed for the treatment of Metabolic Dysfunction-Associated SteatoHepatitis (MASH) cirrhosis and portal hypertension. With a market capitalization of $88.5 ...

The trial tested belapectin, a drug designed for the treatment of Metabolic Dysfunction-Associated SteatoHepatitis (MASH) cirrhosis and portal hypertension. With a market capitalization of $88.5 ...

Galectin Therapeutics Inc. Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo ...

The NAVIGATE trial top-line results showed that while the incidence of varices at 18 months was 43.2% lower in patients treated with belapectin 2 mg vs placebo, the composite endpoint did not ...

The NAVIGATE trial top-line results showed that while the incidence of varices at 18 months was 43.2% lower in patients treated with belapectin 2 mg vs placebo, the composite endpoint did not ...

(GALT), on Tuesday, announced additional data from the NAVIGATE trial showing a significant 68.1% reduction in the incidence of new varices in U.S. patients treated with belapectin. Belapectin ...